Clinical and Molecular Advances in Acute Promyelocytic Leukaemia

  • Hugues de Thé
  • Laurent Degos
  • Raymond P. WarrellJr
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Acute promyelocytic leukaemia (APL) comprises approximately 10% of the acute myeloblastic leukaemias in adults [1,2]. The disease was first recognised as a distinctive clinical entity in the 1950s [3] and it typically presents with a severe bleeding diathesis that is exacerbated by chemotherapy [4–7]. This feature has led to a relatively high rate of early mortality, ranging from 8% to 47% in recent series [4–9], primarily as a consequence of intracranial haemorrhage [9–11]. In this chapter, we review the latest information regarding the molecular genetics and current methods of therapy of this disease.


Retinoic Acid Disseminate Intravascular Coagulation Acute Promyelocytic Leukemia Minimal Residual Disease Retinoic Acid Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stone RM and Mayer RJ: The unique aspects of acute promyelocyte leukemia. J Clin Oncol 1990 (8):1913–1921PubMedGoogle Scholar
  2. 2.
    Mayer RJ, Schiffer CA, Peterson BP et al: Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Semin Oncol 1987 (14 suppl (1)):25–31Google Scholar
  3. 3.
    Hillestad LK: Acute promyelocyte leukemia. Acta Med Scand 1957:189–194Google Scholar
  4. 4.
    Marty M, Ganem G, Fisher J et al: Leucémie aiguë promyelocytaire: étude retrospective de 119 malades traités par daunorubicine. Nouv Rev Fr Hematol 1978 (26):371–378Google Scholar
  5. 5.
    Kantarjian HM, Keating MJ, Walters RS et al: Acute promyelocyte leukemia: the MD Anderson Hospital experience. Am J Med 1986 (80):789–797PubMedCrossRefGoogle Scholar
  6. 6.
    Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD: Acute promyelocyte leukemia: treatment results during a decade at Memorial Hospital. Blood 1989 (73):1116–1122PubMedGoogle Scholar
  7. 7.
    Sanz MA, Jarque I, Martin G et al: Acute promyelocyte leukemia: therapy results and prognostic factors. Cancer 1988 (61):7–13PubMedCrossRefGoogle Scholar
  8. 8.
    Rodeghiero F, Awisati G, Castaman G, Barbui T, Mandelli F: Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990 (75):2112–2117PubMedGoogle Scholar
  9. 9.
    Cordonnier C, Vernant JP, Brun B et al: Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985 (55):18–24PubMedCrossRefGoogle Scholar
  10. 10.
    Gralnick HR and Sultan C: Acute promyelocytic leukemia: haemorrhage manifestation and morphologic criteria. Br J Haematol 1975 (29):373–376PubMedCrossRefGoogle Scholar
  11. 11.
    Jones ME and Saleem A: Acute promyelocytic leukemia: a review of the literature. Am J Med 1978 (65):673–677PubMedCrossRefGoogle Scholar
  12. 12.
    Golomb HM, Rowley J, Vardiman J et al: Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Int Med 1976( 136):825–828CrossRefGoogle Scholar
  13. 13.
    Rowley JD, Golomb HM, Dougherty C: 15/17 translocation: a consistent chromosomal change in acute promyelocyte leukemia. Lancet 1977 (1): 549–550PubMedCrossRefGoogle Scholar
  14. 14.
    Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD: Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984 (76):827–841PubMedCrossRefGoogle Scholar
  15. 15.
    Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon, P: Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988 (80):186–188PubMedCrossRefGoogle Scholar
  16. 16.
    Chomienne C, Ballerini P, Balitrand N et al: The retinoic acid receptor α gene is rearranged in retinoic-acid sensitive promyelocytic leukemia. Leukemia 1990 (4):802–807PubMedGoogle Scholar
  17. 17.
    Longo L, Pandolfi PP, Biondi A et al: Rearrangement and aberrant expression of the retinoic acid receptor a in acute promyelocytic leukemia. J Exp Med 1990 (72): 1571 -1575CrossRefGoogle Scholar
  18. 18.
    Chang KS, Trujillo JM, Ogura T et al: Rearrangement of the retinoic acid receptor gene in acute promyelocytic leukemia. Leukemia 1991 (5):200–204PubMedGoogle Scholar
  19. 19.
    Chen Z, Chen SJ, Tong JH et al: The retinoic acid receptor a gene is frequently disrupted in its 5′ part in Chinese patients with acute promyelocyte leukemia. Leukemia 1990 (5):288–292Google Scholar
  20. 20.
    Borrow J, Goddard AD, Sheer D, Solomon E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990 (249): 1577–1580PubMedCrossRefGoogle Scholar
  21. 21.
    de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 1990 (347):558–561PubMedCrossRefGoogle Scholar
  22. 22.
    Alcalay M, Zangrilli D, Paolo P et al: Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor a locus. Proc Natl Acad Sci (USA) 1991 (88): 1977–1981CrossRefGoogle Scholar
  23. 23.
    Lemmons R, Eilender D, Waldmann R et al: Cloning and characterization of the t(15,17) translocation breakpoint region in acute promyelocytic leukemia. Genes Chromosomes Cancer 1990 (2):79–87CrossRefGoogle Scholar
  24. 24.
    Goddard A, Borrow J, Freemont P et al: Characterisation of a zinc finger gene disrupted by the t(15,17) translocation in acute promyelocytic leukemia. Science 1991 (254):1371–1374PubMedCrossRefGoogle Scholar
  25. 25.
    Kakizuka A, Miller WH Jr, Umesono K et al: Chromosomal translocation t(15,17) in human acute promyelocytic leukemia fuses RAR-α with a novel putative transcription factor PML. Cell 1991 (66):663–674PubMedCrossRefGoogle Scholar
  26. 26.
    de Thé H, Lavau C, Marchio A et al: The PML/RAR- α fusion mRNA generated by the t(15,17) translocation encodes a functionally altered retinoic acid receptor. Cell 1991 (66):675–684PubMedCrossRefGoogle Scholar
  27. 27.
    Pandolfi PP, Grignani F, Alcalay M et al: Structure and origin of the acute promyelocytic leukemia my//RAR-α cDNA and characterization of its retinoid binding and transactivation properties. Oncogene 1991 (6):1285–1292PubMedGoogle Scholar
  28. 28.
    Kastner P, Perez A, Lutz Y et al: Structure, localization and transcriptional properties of two classes of retinoic acid receptor a fusion proteins in acute promyelocytic leukemia: structural similarities with a new family of oncoproteins. EMBO J 1992 (11):629–642PubMedGoogle Scholar
  29. 29.
    Tong JH, Dong S, Geng JP et al: Molecular rearrangements of the myl gene in acute promyelocytic leukemia define a breakpoint cluster region as well as some molecular variants. Oncogene 1992 (7):311–316PubMedGoogle Scholar
  30. 30.
    Chang KS, Lu J, Trujillo JM et al: The t(15;17) translocation in acute promyelocytic leukemia clusters in two different sites of the myl gene: targets for the detection of minimal residual disease by the polymerase chain reaction. Blood 1992 (79):544–558Google Scholar
  31. 31.
    Solomon E, Borrow J, Goddard AD: Chromosome aberrations and cancer. Science 1991 (254): 1153–1160PubMedCrossRefGoogle Scholar
  32. 32.
    Lewin B: Oncogenic changes by regulatory changes in transcription factors. Cell 1992 (64): 303–312CrossRefGoogle Scholar
  33. 33.
    Clarkson B: Acute promyelocyte leukemia: the promise and the paradox. Cancer Cells 1991 (3): 211–219PubMedGoogle Scholar
  34. 34.
    Lovering R, Hanson IM, Borden KLB et al: Identification and preliminary charaterization of a protein motif related to the zinc finger. Proc Natl Acad Sei (USA) 1993 (90):2112–2116CrossRefGoogle Scholar
  35. 35.
    Reddy B, Etkin L, Freemont P: A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends Biochem Sei 1992 (17):344–345CrossRefGoogle Scholar
  36. 36.
    Daniel MT, Koken M, Romagne O et al: PML protein expression in hematopoietic and APL cells. Blood 1993 (82: 1858–1867PubMedGoogle Scholar
  37. 37.
    Koken M, Puvion F, Guillemin MC et al: The t(15; 17) translocation alters a nuclear body in a RA - reversible fashion. EMBO J 1994 (14):1073–1083Google Scholar
  38. 38.
    Dyck J, Maul G, Miller W, Chen D, Kakizuka A, Evans R: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994 (76):333–343PubMedCrossRefGoogle Scholar
  39. 39.
    Chen S, Brand N, Chen A et al: Fusion between a novel kruppel-like finger gene and the retinoic acid receptor a locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J 1993 (12):1161–1167PubMedGoogle Scholar
  40. 40.
    Nagpal S, Saunders M, Kastner P et al: Promoter context and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell 1992 (70): 1007–1019PubMedCrossRefGoogle Scholar
  41. 41.
    Pandolfi PP, Alcalay M, Fagioli M et al: Genomic variability and alternative splicing generate multiple PML/RARa transcripts that encode aberrant PML proteins and PML/RARA isoforms in acute promyelocytic leukemias. EMBO J 1992 (11): 1397–1407PubMedGoogle Scholar
  42. 42.
    erez A, Kastner P, Sethi S, Reibel C, Chambon P: PML/RAR-α homodimers, distinct DNA-binding properties and heterodimeric interactions with RXRs. EMBO J 1993 (12):3171–3182PubMedGoogle Scholar
  43. 43.
    Grignani F, Ferrucci PF, Testa U et al: The acute promyelocytic leukemia-specific PML/RAR α fusion protein inhibits differentation and promotes survival of myeloid precursor cells. Cell 1993 (74) 423–431PubMedCrossRefGoogle Scholar
  44. 44.
    Tobler A, Dawson Ml, Koeffler HP: Retinoids structure-function relationship in normal and leukemic hematopoiesis. J Clin Invest 1986 (78 303–309PubMedCrossRefGoogle Scholar
  45. 45.
    Douer D and Koeffler HP: Retinoic acid enhances colony stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res 1982 138):193–201PubMedCrossRefGoogle Scholar
  46. 46.
    Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL60) by retinoic acid. Proc Natl Acad Sei (USA) 1980( 77):2936–2940CrossRefGoogle Scholar
  47. 47.
    Shroeder C, Gibson L, Zenke M, Beug H: Modulation of normal erythroid differentiation by the endogenous thyroid and retinoid acid receptors: possible targets for v-erb a oncogene action. Oncogene 1992 (7):217–227Google Scholar
  48. 48.
    Collins SJ, Robertson KA, Mueller L: Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-a). Mol Cell Biol 1990 (10):2154–2163PubMedGoogle Scholar
  49. 49.
    Tsai S, Bartelmez S, Heyman R, Damm K, Evans R, Collins S: A mutated retinoic acid receptor a exhibiting dominant negative activity alters the lineage development of a multi-potent hematopoietic cell line. Genes Devel 1992 (6):2258–2269PubMedCrossRefGoogle Scholar
  50. 50.
    Tsai S and Collins S: A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocytic stage. Proc Natl Acad Sci (USA) 1993 (90):7153–7157CrossRefGoogle Scholar
  51. 51.
    Sharif M and Privalsky M: v-erbA oncogene function in neoplasia correlates with its ability to repress RAR action. Cell 1991 (66):885–893PubMedCrossRefGoogle Scholar
  52. 52.
    Rousselot P, Hardas B, Castaigne S et al: The PML-RAR gene product of the t(15;17) translocation inhibits retinoic acid induced granulocytic differentiation. Oncogene 1994 (in press)Google Scholar
  53. 53.
    Ascoli CA and Maul GG: Identification of a novel nuclear domain. J Cell Biol 1991 (112):785–795PubMedCrossRefGoogle Scholar
  54. 54.
    de Thé G, Rivière M, Bernhard W: Bull Cancer 1960 (47):570–584Google Scholar
  55. 55.
    Szostecki C, Guldner HH, Netter HJ, Will H: Isolation and characterisation of a cDNA encoding a human nuclear antigen predominantly recognized by auto antibodies of patients with primary billiary cirrhosis. J Immunol 1990 (145):4338–4347PubMedGoogle Scholar
  56. 56.
    Eilers M, Picard D, Yamwnoto K, Bishop M: Chimaeras of the myc oncoprotein and the steroid receptors cause hormone-dependent transformation of cells. Nature 1989 (340):66–68PubMedCrossRefGoogle Scholar
  57. 57.
    Mangelsdorf D and Evans R: The retinoid receptor network. In: McKnight S and Yamamoto K (eds) Transcriptional Regulation. Cold Spring Harbor Press, Cold Spring Harbor, NY. Vol. 2, pp 1137–1167Google Scholar
  58. 58.
    Ganem G, Fischer J, Marty M et al: Prognostic factors in acute promyelocytic leukemia (APL): a retrospective study of 101 patients treated by daunorubicin containing remission induction regimen. Blood 1983 (63) suppl):171aGoogle Scholar
  59. 59.
    Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ: Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989 (3):23–28PubMedGoogle Scholar
  60. 60.
    Berman E, Little C, Kher U et al: Prognostic analysis of patients with acute promyelocytic leukemia (APL). Blood 1991 (78 suppl):43aGoogle Scholar
  61. 61.
    Thomas X, Archimbaud E, Treille-Ritouet, Fiere D: Prognostic factors in acute promyelocytic leukemia: a retrospective study of 67 cases. Leuk Lymphoma 1991 (4):249–256CrossRefGoogle Scholar
  62. 62.
    Tallman MS and Kwaan HC: Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992(79):543–553PubMedGoogle Scholar
  63. 63.
    Gouault-Heilmann M, Chardon E, Sultan C, Josso F: The procoagulant factor of leukemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 1975 (30):151–158PubMedCrossRefGoogle Scholar
  64. 64.
    Kubota T, Andoh K, Sadakata H, Tanaka H, 87 Koboyashi N: Tissue factor released from leukemic cells. Thromb Haemost 1991 (65):59–63PubMedGoogle Scholar
  65. 65.
    Bauer KA and Rosenberg RD: Thrombin generation 88 in acute promyelocytic leukemia. Blood 1984 (64): 791–796PubMedGoogle Scholar
  66. 66.
    Bennett B, Booth A, Croll A, Dawson AA: The bleeding disorder in acute promyelocytic leukae- 89 mia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989 (71):511–517PubMedCrossRefGoogle Scholar
  67. 67.
    Wilson EL, Jacobs P, Dowdle EB: The secretion of plasminogen activators by human myeloid leuke- 90 mic cells in vitro. Blood 1983 (61):568–574PubMedGoogle Scholar
  68. 68.
    Francis RB and Seyfert U: Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation. Clinicopathologic correla- 91 tions. J Lab Clin Med 1987 (110):541–547PubMedGoogle Scholar
  69. 69.
    Sterrenberg L, Haak HL, Brommer EJP, Nieuwenhuizen W: Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985 (15): 126–133 92PubMedGoogle Scholar
  70. 70.
    Saito M, Asakura H, Uotani C, Jokaji H, Kumabashiri I, Matsuda T: Quantitative estimation of elastase-a-1 proteinase inhibitor (E-aPI) complex in leukemia: marked elevation in cases of 93 acute promyelocytic leukemia. Thromb Res 1989 (53):163–171PubMedCrossRefGoogle Scholar
  71. 71.
    Avvisati G, ten Cate JW, Sturk A, Lamping R, Petti MC, Mandelli F: Acquired a-2-antiplasmin deficien- 94 cy in acute promyelocytic leukaemia. Br J Haematol 1988 (70):43–48PubMedCrossRefGoogle Scholar
  72. 72.
    Brower NS and Harpel PC: Proteolytic cleavage and inactivation of a-2 plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982 (257):9849–9854 95PubMedGoogle Scholar
  73. 73.
    Sakata Y, Murakami T, Noro A, Mori K, Matsuda M: The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991 (96) 77: 1949–1957Google Scholar
  74. 74.
    Schwartz BS, Williams EC, Conlan MG, Mosher DF: Epsilon-aminocaproic acid in the treatment of 97 patients with acute promyelocytic leukemia and acquired a-2-plasmin inhibitor. Ann Intern Med 1986 (105):873–877PubMedGoogle Scholar
  75. 75.
    Scrobohaci ML, Dombret H, Ghorra P et al: 98 Disseminated intravascular coagulation (DIC) and/or primary fibrinolysis in acute promyelocytic leukemia, effect of all -trans retinoic acid treatment. Blood 1991 (78 suppl): (48a) 99Google Scholar
  76. 76.
    Avvisati G, Mandelli F, Petti MC et al: Idarubicin as a single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group (GIMEMA). 100 Eur J Haematol 1990 (44):257–260PubMedCrossRefGoogle Scholar
  77. 77.
    Stone RM, Maguire M, Goldberg MA, Antin JH, Rosenthal DS, Mayer RJ: Complete remission in acute promyelocytic leukemia despite persistance 101 of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988 (71):690–696PubMedGoogle Scholar
  78. 78.
    Head DR, Kopecky K, Hewlett J et al: Survival with cytotoxic therapy in acute promyelocytic leukemia: 102 a SWOG report. Blood 1991 (78 suppl):268aGoogle Scholar
  79. 79.
    Kantarjian H, Keating M, Walters R et al: Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer 1987 (59):1258–1263PubMedCrossRefGoogle Scholar
  80. 80.
    Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF: Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood 1983 (62): 1211–1217PubMedGoogle Scholar
  81. 81.
    Daenen S, Vellenga E, van Dobbenburgh OA, Halie MR: Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia. Blood 1986 (67):559–561PubMedGoogle Scholar
  82. 82.
    Fontana JA, Rogers JS, Durham JP: The role of 13- cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 1989 (57):209–217CrossRefGoogle Scholar
  83. 83.
    Wijermans PW, Rebel VI, Ossenkoppele GJ, Huijens PC, Langenhuijsen MMAC: Combined pro-coagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation. Blood 1989 (73):800–805PubMedGoogle Scholar
  84. 84.
    Chomienne C, Ballerini P, Balitrand N et al: All-frans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990 (76): 1710–1717PubMedGoogle Scholar
  85. 85.
    Degos L, Chomienne C, Daniel MT et al: Treatment of first relapse in acute promyelocytic leukemia with all -trans retinoic acid. Lancet 1990 (336): 1440–1441PubMedCrossRefGoogle Scholar
  86. 86.
    Runde V, Aul C, Sudhoft T, Heyll A, Schneider W: Retinoic acid in the treatment of acute promyelocytic leukemia: inefficacy of the 13-c/s isomer and induction of complete remission by the all-trans isomer complicated by thromboembolic events. Ann Hematol 1992 (64):270–272PubMedCrossRefGoogle Scholar
  87. 87.
    Huang ME, Ye YC, Chen SR et al: All-frans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia - Report of 6 cases. Chin Med J 1987 (100):949–953PubMedGoogle Scholar
  88. 88.
    Huang ME, Ye YC, Chen SR et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988 (72):567–572PubMedGoogle Scholar
  89. 89.
    Castaigne S, Chomienne C, Daniel MT et al: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. clinical results. Blood 1990 (76): 1704–1709PubMedGoogle Scholar
  90. 90.
    Warrell RP Jr, Frankel SR, Miller WH Jr et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all -trans retinoic acid). N Engl J Med 1991 (324): 1385–1393PubMedCrossRefGoogle Scholar
  91. 91.
    Chen ZX, Xue YQ, Zhang RI et al: A clinical and experimental study on all -trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991( 78): 1413–1419PubMedGoogle Scholar
  92. 92.
    Ohno R, Yoshida H, Naoe T et al: All-frans retinoic acid (ATRA) as a differentiation therapy for refractory acute promyelocytic leukemia (APL). Proc Am Assoc Cancer Res 1992 (33):234Google Scholar
  93. 93.
    Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR: Treatment of acute promyelocytic leukemia with all -trans retinoic acid: an update of the New York experience. Leukemia 1994 (8):929–933PubMedGoogle Scholar
  94. 94.
    Sun GL, Huang YG, Chang XF, Jiang GS, Zhang T: Clinial study on all -trans retinoic acid in treatmentof 544 cases of acute promyelocytic leukemia. Chin J Hematol 1992 (13):135–137CrossRefGoogle Scholar
  95. 95.
    Frankel SR, Eardley A, Heller G et al: All -trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Mèd 1994 (120):278–286Google Scholar
  96. 96.
    Eardley AM, Heller G, Warrell RP Jr: Morbidity and costs of remission induction therapy with all -trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia. Leukemia 1994 (8):934–939PubMedGoogle Scholar
  97. 97.
    Muindi J, Frankel SR, Miller WH et al: Continuous treatment with all -trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and “resistance” in acute promyelocytic leukemia. Blood 1992 (79):299–303PubMedGoogle Scholar
  98. 98.
    Miller WH Jr, Levine K, DeBiasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by reverse transcription polymerase chain reaction assay for the PMLVRAR-a fusion mRNA. Blood 1993 (82): 1689–1694PubMedGoogle Scholar
  99. 99.
    Lo Coco F, Avvisati G, Diverio D et al: Molecular evaluation of response to all -trans retinoic acid therapy in patients with acute promyelocytic leukemia. Blood 1991 (77):1657–1659PubMedGoogle Scholar
  100. 100.
    Miller WH Jr, Jakubowski A, Warrell RP Jr: 9-c/s retinoic acid (RA), the RXR ligand, is an effective cytodifferentiating agent for acute promyelocytic leukemia (APL) cells. Blood 1992 (80 suppl):108aGoogle Scholar
  101. 101.
    Biondi A, Rambaldi A, Pandolfi PP, et al. Molecular monitoring of the my RAR-a fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992 (80):492–497PubMedGoogle Scholar
  102. 102.
    Castaigne S, Balitrand N, deThe H, Dejean A, Degos L, Chomienne C: A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992 (79):3110–3115PubMedGoogle Scholar
  103. 103.
    Chen SJ, Chen Z, Chen A et al: Occurrence of distinct PML/RAR a fusion gene isoforms in patients with acute promyelocytic leukemia detected by the polymerase chain reaction. Oncogene 1992 (7): 1223–1232PubMedGoogle Scholar
  104. 104.
    Borrow J, Goddard A, Gibbons B et al: Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML/RAR-a and RAR-cc/PML fusion transcripts. Br J Haematol 1992 (82):529–540PubMedCrossRefGoogle Scholar
  105. 105.
    Lo Coco F, Diverio D, Pandolfi PP et al: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992 (340): 1437–1438PubMedCrossRefGoogle Scholar
  106. 106.
    Chen Z, Guidez F, Rousselot P et al: PLZF-RARa fusion proteins generated from the variant t(11;17) (q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci (USA) 1994 (91): 1178–1182CrossRefGoogle Scholar
  107. 107.
    Fenaux P, Le Deley MC, Castaigne S et al: Effect of all -trans retinoic acid in newly diagnosed acute promyelocytic leukemia; results of a multicenter randomized trial. Blood 1993 (82):3241–3249PubMedGoogle Scholar
  108. 108.
    Fenaux P, Castaigne S, Dombret H et al: All -trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992 (80):2176–2181PubMedGoogle Scholar
  109. 109.
    Warrell RP Jr, de Thé H, Wang Z-Y, Degos L: Acute promyelocytic leukemia. N Engl J Med 1993 (329): 177–189PubMedCrossRefGoogle Scholar
  110. 110.
    Robertson KA, Emami B, Collins SJ: Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992 (80):1885–1889PubMedGoogle Scholar
  111. 111.
    Lefebvre P, Thomas G, Gourmel B et al: Pharmacokinetics of oral all -trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991 (5):1054–1058PubMedGoogle Scholar
  112. 112.
    Muindi J, Frankel S, Huselton C et al: Clinical pharmacology of oral all -trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992 (52:2138–2142PubMedGoogle Scholar
  113. 113.
    Muindi JF and Young CW: Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all -trans retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 1993 (53): 1226–1229PubMedGoogle Scholar
  114. 114.
    Muindi, JF Scher HI, Rigas JR, Warrell RP Jr, Young CW: Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans retinoic acid in patients with advanced cancer. Cancer Res 1994 (54):2125–2128PubMedGoogle Scholar
  115. 115.
    Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C: Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992 (52):3329–3334PubMedGoogle Scholar
  116. 116.
    Elliott S, Taylor K, White S et al: Proof of differentiate mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992 (79): 1916–1919PubMedGoogle Scholar
  117. 117.
    Bashford J, Szer J, Wiley JS et al: Treatment of acute promyelocytic leukemia relapsing after allogeneic bone marrow transplantation with all- trans retinoic acid: suppression of the leukemic clone. Br J Haematol 1991 (79):331–334PubMedCrossRefGoogle Scholar
  118. 118.
    Fearon ER, Burke PJ, Schiffer CA et al: Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphoblastic leukemia. N Engl J Med 1986 (315):15–24PubMedCrossRefGoogle Scholar
  119. 119.
    Martin S, Bradley J, Cotter T: HL-60 cells cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990 (79):448–453PubMedCrossRefGoogle Scholar
  120. 120.
    Lanotte M, Martin V, Najman S et al: NB4, a maturation inducible cell-line with t(15;17) marker isolated from a human promyelocytic leukaemia (M3). Blood 1991 (77):1080–1086PubMedGoogle Scholar
  121. 121.
    Chomienne C, Balitrand N, Ballerini P, Castaigne S, de The H, Degos L: All -trans retinoic acid modulates retinoic acid receptor-a in promyelocytic cells. J Clin Invest 1991 (88):2150–2154PubMedCrossRefGoogle Scholar
  122. 122.
    Leroy P, Krust A, Zelent A et al: Multiple isoforms of the mouse retinoic acid receptor a are generated by alternative splicing and differential induction by retinoic acid. EMBO J 1991 (10):59–69PubMedGoogle Scholar
  123. 123.
    Hughes TP, Morgan GJ, Martiat P, Goldman JM: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction for the rearranged retinoic acid receptor-a predicts polymerase chain reaction in predicting relapse. Blood 1991 (77):874–878PubMedGoogle Scholar
  124. 124.
    Miller WH Jr, Warrell RP Jr, Frankel SR et al: Novel retinoic acid receptor-a transcripts in acute promyelocyte leukemia responsive to all-trans retinoic acid. JNC11990 (82): 1932–1933Google Scholar
  125. 125.
    Levin A, Struenbecker L, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, Grippo JF. 9 eis retinoic acid stereoisomer binds and activates the nuclear receptor RXR-α. Nature 1992 (335):359–361CrossRefGoogle Scholar
  126. 126.
    Heyman RA, Mangelsdorf DF, Dyck JA, Stein RB, Eichele G, Evans RM: 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992 (68):397–406PubMedCrossRefGoogle Scholar
  127. 127.
    Lehmann JM, Jong L, Fanjul A et al: Retinoids selective for retinoid X receptor response pathways. Science 1992 (258):1944–1946PubMedCrossRefGoogle Scholar
  128. 128.
    Kizaki M, Norman AW, Bishop JE, Lin C-W, Karmakar A, Koeffler HP: 1,25-dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells. Blood 1991 (77): 1238–1247PubMedGoogle Scholar
  129. 129.
    Perlman K, Kutner A, Prahl J et al: 24-homologated 1,25-dihydroxyvitamin D3 compounds: separation of calcium and cell differentiation activities. Biochemistry 1990(29): 1 90–196CrossRefGoogle Scholar

Copyright information

© Springer-verlag Berlin heidelberg 1995

Authors and Affiliations

  • Hugues de Thé
    • 1
  • Laurent Degos
    • 1
  • Raymond P. WarrellJr
    • 2
  1. 1.Hôpital St. LouisInstitut Universitaire d’HématologieParisFrance
  2. 2.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations